Cite
HARVARD Citation
Tocoian, A. et al. (2015). First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. pp. 1045-1056. [Online].